Q-omics provides the consensus-scored TEFM profile across patient tissues and cancer cell-line models. TEFM expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TEFM is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TEFM protein abundance shows 22,835 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, HNSC, and LSCC as cancer lineages where TEFM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEFM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEFM survival associations across molecular data types. TEFM RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEFM RNA expression–survival associations across cancer types. High TEFM expression shows unfavorable associations in LIHC, MESO, ACC, KICH, LGG and KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TEFM RNA expression.
This table summarizes TEFM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TEFM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEFM shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BLCA, LIHC and STAD. The HNSC box plot shows higher TEFM RNA expression in tumor versus normal tissue (log2 FC = +0.638, t-test p < 0.001).
This table shows molecular features associated with TEFM in patient tissues and cancer cell lines. In patient samples, TEFM shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TEFM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
